TORONTO, ON --(Marketwired - September 04, 2014) - Medtronic of Canada today announced the Health Canada license of enhanced Enlite™, the latest iteration of the company's Enlite glucose sensor. The enhanced Enlite is a component of continuous glucose monitoring (CGM) technology and is designed to provide a more consistent and comfortable experience(1) for people using CGM.
Insulin pumps with integrated CGM provide continuous insulin delivery and offers lifestyle flexibility for people living with diabetes. In addition to delivering small amounts of insulin around-the-clock, these integrated systems provide glucose values at 5-minute intervals, and predictive alerts that can be preset to let users know when glucose levels are rapidly changing, trending out of range or are out of range.
The enhanced Enlite sensor is used as part of the MiniMed ® Veo ™ system, an integrated insulin pump and CGM system, which is clinically proven to provide better glucose control in people with Type-1 diabetes (T1D) than multiple daily injections(2). Better glucose control reduces the risk of long-term diabetes complications, such as eye disease, kidney disease and nerve damage(3). The MiniMed Veo system includes a feature called Low Glucose Suspend, which is clinically proven to significantly reduce hypoglycemia (low blood glucose)(4)(5) -- a dangerous syndrome that can cause confusion, disorientation, loss of consciousness and, in severe cases, even death.
The enhanced Enlite improvements include:
- An 80 percent reduction in implanted volume (the size of what goes inside the patient's body) for a more comfortable experience
- New chemistry pattern and layers, designed for more consistent daily performance through the life of the sensor
- Improved sensor-to-transmitter connection
- Updated sensor adhesive patch design to help reduce likelihood of skin irritation
"Enhanced Enlite is the next step in delivering CGM technology that provides patients with a more advanced sensor performance and improved comfort. At Medtronic, we're committed to developing technology that improves clinical outcomes for people living with diabetes. This technology innovation, combined with the clinically proven Low Glucose Suspend in the Medtronic MiniMed® Veo™ insulin pump system, marks another critical milestone on the road towards the artificial pancreas," says Dr. Francine R. Kaufman, Chief Medical Officer and Vice President of Global Clinical and Medical Affairs at Medtronic Diabetes.
The enhanced Enlite has been licensed by Health Canada and will be available to Canadians living with diabetes in early October, 2014. The product is not approved for use in the U.S.
About the Diabetes Business at Medtronic The Diabetes business at Medtronic is the world leader in advanced diabetes technology solutions, including insulin pump technology, continuous glucose monitoring systems and data management software, as well as world-class, 24/7 expert consumer and professional service and support.
About Medtronic of Canada Medtronic of Canada Ltd. ( www.medtronic.ca or www.medtronicdiabetes.ca ) is a trusted Canadian leader delivering innovative health system solutions and advanced medical technologies to alleviate pain, restore health, and extend life in the areas of cardiovascular medicine, diabetes, spinal and neurosurgery, and ear, nose, throat surgery. Medtronic is proud to employ more than 700 Canadians. Headquartered in Brampton, Ontario, Medtronic has regional offices in Vancouver and Montreal, including a manufacturing facility, Medtronic CryoCath, located in Pointe-Claire, Quebec.
About Medtronic Medtronic, Inc. ( www.medtronic.com ), headquartered in Minneapolis, is the global leader in medical technology -- alleviating pain, restoring health and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic, Inc.'s periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results.
(1) Data on File. (2) Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med.2010;363:311-320. (3) The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994; 125: 177-88 (4) Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-Based Insulin Pump Interruption for Reduction of Hypoglycemia. N Engl J Med . June 2013. (5) Ly.T et.al, JAMA September 2013, volume 310, number 12, page 1247
Contact: Monika Paquette Medtronic of Canada Public Relations 905-460-3573
